Pregled bibliografske jedinice broj: 212833
Molecular monitoring of aml1/eto transcript in aml patients at diagnosis and follow-up by quantitative PCR
Molecular monitoring of aml1/eto transcript in aml patients at diagnosis and follow-up by quantitative PCR // Abstracts of the 18th International Congress of Clinical Chemistry ; u Clinical Chemistry and Laboratory Medicine 40 (2002) (S)
Kyoto, Japan, 2002. str. S115-S115 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 212833 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Molecular monitoring of aml1/eto transcript in aml patients at diagnosis and follow-up by quantitative PCR
Autori
Zadro, Renata ; Kastelić, R. ; Bulum, Joško ; Rajić, Ljubica ; Stavljenić Rukavina, Ana ; Labar, Boris
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 18th International Congress of Clinical Chemistry ; u Clinical Chemistry and Laboratory Medicine 40 (2002) (S)
/ - , 2002, S115-S115
Skup
International Congress of Clinical Chemistry (18 ; 2002)
Mjesto i datum
Kyoto, Japan, 18.10.2002. - 22.10.2002
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
molecular monitoring; aml1/eto transcript
Sažetak
The t(8 ; 21) is one of the most common translocations in acute myeloid leukemia (AML) occurring in approximately 20% of adult and 40% of pediatric AML-M2 patients. The result of this translocation is the fusion gene AML1/ETO whose transcripts can be detected by qualitative and quantitative PCR in patients at diagnosis as well as in clinical remission. Using Light Cycler technology, we have analyzed 50 samples of 13 patients who were positive for AML1/ETO transcript at diagnosis by qualitative RT-PCR. For all the patients studied the positive results by qualitative RT-PCR were in agreement with the results obtained by Light Cycler technology. By comparison of two methods we established the cut-off value for aml1/eto transcript:G-6-PDH ratio as 0.27 while the same ratio ranged 0.30-2.35 at diagnosis. Additionally, six patients with t(8 ; 21) AML were studied by quantitative RT-PCR at different time intervals (1-16 months) after therapy was started. We observed a constant decrease in aml1/eto transcript:G-6-PDH ratio from the time of diagnosis (range 1.0-2.35) to below 0.30, 1 to 3 months after the beginning of therapy. We conclude that quantification of residual disease with Real Time RT-PCR is a reliable and sensitive method to monitor the dynamics of disappearance of malignant clone.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE